At a glance

DSIP Quick Reference

Nasal reported range: Members only
Sign in to view dosing details.
SubQ community range: Members only
Sign in to view dosing details.
Cycle: Members only
Sign in to view dosing details.
Research routes: Nasal Spray / SubQ Injection
Community protocols; not clinically validated

Overview

What Is DSIP?

DSIP stands for Delta Sleep-Inducing Peptide. It is a naturally occurring nine-amino-acid peptide first described in the 1970s after Swiss researchers isolated DSIP-like material from the cerebral venous blood of rabbits during experimentally induced slow-wave sleep.

Its sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Early research linked the peptide to delta-wave activity, sleep regulation, endocrine signaling, stress responses, and pain modulation. DSIP has also been studied for its ability to cross the blood-brain barrier, although its endogenous biology, receptor, precursor, and exact physiological role remain unresolved.

Unlike conventional sedatives, DSIP is not generally described as a direct “knockout” agent. The theory is that it may influence sleep architecture and help normalize disturbed sleep rather than simply suppress consciousness. That distinction remains provisional because published human findings are mixed.

Small studies from the 1980s reported improved sleep duration, fewer awakenings, or better daytime function, but later controlled work in chronic insomnia found modest or limited benefit. DSIP should not be presented as a proven treatment for insomnia.

DSIP is rapidly degraded in vitro, with reported half-life estimates around 15 minutes. Carrier binding or other biological factors may extend activity in vivo, but no modern human pharmacokinetic profile has been established.

Intranasal DSIP has been examined in a small human neurophysiology study involving P300 brain-response measurements and in animal research involving stroke recovery. Those studies support the route as biologically plausible, but they do not establish an effective intranasal dose for insomnia or validate current community spray protocols.

Mechanism

DSIP Mechanism of Action

Sleep architecture

DSIP was originally identified through experiments involving slow-wave sleep and delta-wave activity. The proposed role is modulation of sleep patterns rather than a conventional direct sedative effect.

Stress and endocrine signaling

Experimental research links DSIP to stress responses and endocrine signaling. Reliable cortisol reduction or direct growth-hormone stimulation has not been established in modern human trials.

Unresolved target

The receptor, precursor, and exact physiological role remain unresolved. Rapid in-vitro degradation also makes a precise human duration of action difficult to infer.

Human response

Small older studies produced mixed results. A controlled chronic-insomnia study found limited changes and did not support a major short-term therapeutic benefit. 1992 controlled study.

Research findings

DSIP Benefits

The evidence base includes small older human studies and more recent animal research. Findings are mixed and do not establish broad clinical efficacy.

Evidence: small older human studies and animal research

Sleep Quality

Some older studies reported longer sleep, fewer awakenings, faster sleep onset, or improved subjective sleep quality. Results in chronic insomnia were inconsistent, and one controlled study concluded that short-term treatment was unlikely to provide major therapeutic benefit.

Sleep Architecture

Early human work suggested DSIP could improve disturbed sleep without clearly suppressing REM sleep. Because the studies were small and methodologically dated, this should not be treated as a settled effect.

Stress Response

Animal studies suggest stress-protective effects under hypoxia and possible modulation of endocrine stress signaling. Human evidence for reliable cortisol reduction is limited.

Pain Relief

A 1984 clinical pilot involving patients with chronic severe pain reported reductions in pain severity and improved mood, with some patients reducing analgesic use. The study was small and exploratory.

Withdrawal Support

An older 107-patient study reported favorable outcomes during opiate and alcohol withdrawal. These findings have not been confirmed in modern randomized trials and should not replace medically supervised detoxification.

Growth Hormone Support

Because growth hormone release is linked to slow-wave sleep, improved sleep could indirectly support normal GH physiology. Direct GH-stimulating effects remain uncertain and are not established in modern human trials.

Neuroprotection

A 2021 rat stroke study found improved motor recovery after intranasal DSIP at 120mcg/kg, despite no significant reduction in infarct size. This remains animal evidence only. Rat stroke study.

Protocol planning

DSIP Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

Preparation

DSIP Reconstitution & Nasal Preparation

Nasal spray preparation example

10mg DSIP in 5mL final volume

At 0.1mL per spray200mcg/spray

Nasal preparation

1

Prepare

Our reported diluent preference is 50% sterile, preservative-free 0.9% saline and 50% bacteriostatic 0.9% sodium chloride. The bacteriostatic component contains a preservative. Use a suitable metered bottle and clean handling.

2

Measure the final mixture

The example contains 10mg DSIP in 5mL final liquid volume, using equal parts of the two diluents: 2.5mL sterile saline and 2.5mL bacteriostatic sodium chloride. This gives 2mg/mL.

3

Confirm pump output

At a measured 0.1mL per spray, 2mg/mL delivers 200mcg per spray. Check the bottle specification and actual output; another pump volume changes the amount per spray.

4

Storage

Keep refrigerated and protected from light according to the formulation instructions. Record the prep date in your research journal.

Reconstitution Example

10mg vial + 2mL BAC water

Result5mg/mL

SubQ vial preparation

1

Prepare

Wash hands, clean the work surface, and wipe vial stoppers with alcohol. Allow them to dry.

2

Add diluent slowly

Use a new sterile syringe and needle to add 2mL BAC water down the inside vial wall when compatible with the formulation.

3

Dissolve gently

Swirl or roll until dissolved; do not shake.

4

Storage

Store refrigerated at 2–8°C and protected from light, following the product instructions. Record the reconstitution date in your research journal.

N=1 reports

DSIP Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users commonly describe deeper, more continuous sleep with fewer middle-of-the-night awakenings.
Many report feeling calmer and more rested on waking without the heavy grogginess associated with conventional sleep aids.
Vivid dreams, stronger dream recall, and occasional lucid dreaming are frequently reported.

Negative & Mixed Reports

Some users notice little or no effect despite an adequate trial period.
Higher doses are sometimes reported to disrupt sleep or cause next-day sedation.
Some users report temporary rebound sleep difficulty after prolonged daily use.
Intranasal use can cause temporary nasal dryness or irritation.

Stacking & synergy

DSIP Stacking & Synergy

These are community-discussed pairings rather than validated combination protocols. Sedatives, benzodiazepines, opioids, sedating antihistamines, alcohol, and other sleep aids may add to sedation.

DSIP + Epitalon

The community rationale pairs circadian-timing support with DSIP’s focus on sleep quality and continuity. This is a proposed pairing, not an established combination effect.

DSIP + Pinealon

Discussed when poor sleep overlaps with cognitive fatigue or disrupted day-night patterns. Pinealon is used for broader neuroregulatory goals while DSIP is used around bedtime; clinical combination data are lacking.

DSIP + GH Peptides

Community users sometimes add DSIP when nighttime CJC-1295 + ipamorelin or tesamorelin appears to disrupt sleep. Track sleep changes and the timing of each compound separately.

DSIP + Semax or Selank

Some users combine morning Semax or Selank with bedtime DSIP for daytime cognitive goals and nighttime sleep optimization. No published interaction data establish the combination’s safety or benefit.

Safety notes

DSIP Side Effects & Safety

Older clinical studies generally described DSIP as well tolerated over short treatment periods. Samples were small and study designs were dated; long-term safety has not been established.

Claims of no dependency, respiratory depression, or rebound insomnia reflect limited observations rather than definitive safety evidence for prolonged use.

Common User Reports

Mild headache.
Temporary grogginess when the dose is too high.
Slight mood fluctuations.
Vivid dreams.

Less Common Reports

Brief anxiety.
Extended sleepiness into the next day at higher doses.
Temporary worsening of sleep after stopping prolonged daily use.
Nasal dryness or irritation.

DSIP Precautions

Avoid or discuss with a clinician if

Known hypersensitivity to DSIP or any formulation component.
Pregnant or breastfeeding; safety data are absent.

Use caution with

Sedatives, benzodiazepines, sleep medications, alcohol, or sedating antihistamines; additive effects are possible.
Opioid use; sedation and opioid-pathway interactions are incompletely understood.
Severe chronic insomnia; controlled evidence suggests limited benefit.
Kidney or liver impairment; human clearance data are limited.

Regulatory status: DSIP is not FDA approved in the United States. It should not be represented as an approved medication.

Final verdict

Peptide Protocols Verdict on DSIP

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

We rate DSIP as a useful but highly individual sleep peptide. For those who respond well, it can deliver deeper, more restorative sleep, improved HRV, and better recovery by helping restore normal sleep patterns and taking the edge off the stress axis.

That said, a large portion of people see little to no benefit, likely due to genetic differences in how their bodies process it. Community reports show wide variation in response rates, with many users falling into the non-responder category.

Important context: DSIP will not fix bad sleep hygiene. If you’re drinking caffeine late, scrolling in bed or binging shows into the wee hours of the night, no peptide is going to save you. Sleep hygiene sits upstream of every sleep tool. DSIP is often misused because people treat it like “Ambien in a vial” — expecting to run themselves into the ground all day, administer before bed, and wake up brand new and it just doesn’t work that way.

The best way to know if it’s actually working for you is objective data from a good sleep tracker (Oura, Apple Watch, etc.). Subjective feelings alone are often unreliable.

End of the day, definitely worth testing if sleep optimization is a priority and your fundamentals are already solid. Not a universal fix and works best for those who randomly wake up in the middle of the night or toss and turn a lot.

We like it and use DSIP periodically. We also found that running it 3–5 consecutive days followed by 2–3 days off works best. When or if the results fade, take a break for 1–2 weeks and start again.